Cotton François, Hermier Marc
MRI Center, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France.
Eur Radiol. 2006 Nov;16 Suppl 7:M16-26. doi: 10.1007/s10406-006-0192-3.
Accurate MRI characterization of brain lesions is critical for planning therapeutic strategy, assessing prognosis and monitoring response to therapy. Conventional MRI with gadolinium-based contrast agents is useful for the evaluation of brain lesions, but this approach primarily depicts areas of disruption of the blood-brain barrier (BBB) rather than tissue perfusion. Advanced MR imaging techniques such as dynamic contrast agent-enhanced perfusion MRI provide physiological information that complements the anatomic data available from conventional MRI. We evaluated brain perfusion imaging with gadobenate dimeglumine (Gd-BOPTA, MultiHance; Bracco Imaging, Milan, Italy). The contrast-enhanced perfusion technique was performed on a Philips Intera 1.5-T MR system. The technique used to obtain perfusion images was dynamic susceptibility contrast-enhanced MRI, which is highly sensitive to T2* changes. Combined with PRESTO perfusion imaging, SENSE is applied to double the temporal resolution, thereby improving the signal intensity curve fit and, accordingly, the accuracy of the derived parametric images. MultiHance is the first gadolinium MR contrast agent with significantly higher T1 and T2 relaxivities than conventional MR contrast agents. The higher T1 relaxivity, and therefore better contrast-enhanced T1-weighted imaging, leads to significantly improved detection of BBB breakdown and hence improved brain tumor conspicuity and delineation. The higher T2 relaxivity allows high-quality T2*-weighted perfusion MRI and the derivation of good quality relative cerebral blood volume (rCBV) maps. We determined the value of MultiHance for enhanced T2*-weighted perfusion imaging of histologically proven (by surgery or stereotaxic biopsy) intraaxial brain tumors (n = 80), multiple sclerosis lesions (n = 10), abscesses (n = 4), neurolupus (n = 15) and stroke (n = 16). All the procedures carried out were safe and no adverse events occurred. The acquired perfusion images were of good quality in all but two patients. Our findings confirm that high relaxivity contrast agents such as MultiHance are ideal for use in perfusion MRI of the central nervous system.
脑病变的准确磁共振成像(MRI)特征对于制定治疗策略、评估预后以及监测治疗反应至关重要。基于钆的造影剂的传统MRI对脑病变的评估很有用,但这种方法主要描绘血脑屏障(BBB)破坏的区域,而非组织灌注。动态对比剂增强灌注MRI等先进的MR成像技术提供了补充传统MRI解剖数据的生理信息。我们评估了钆贝葡胺(Gd - BOPTA,MultiHance;意大利米兰的博莱科影像公司)用于脑灌注成像的情况。对比增强灌注技术在飞利浦Intera 1.5 - T MR系统上进行。用于获取灌注图像的技术是动态磁敏感对比增强MRI,其对T2变化高度敏感。结合快速采集弛豫增强(PRESTO)灌注成像,同时应用敏感度编码(SENSE)技术使时间分辨率提高一倍,从而改善信号强度曲线拟合,进而提高导出的参数图像的准确性。MultiHance是首个钆MR造影剂,其T1和T2弛豫率显著高于传统MR造影剂。较高的T1弛豫率以及因此更好的对比增强T1加权成像,使得血脑屏障破坏的检测显著改善,从而提高脑肿瘤的清晰度和轮廓显示。较高的T2弛豫率允许进行高质量的T2加权灌注MRI以及生成高质量的相对脑血容量(rCBV)图。我们确定了MultiHance在组织学确诊(通过手术或立体定向活检)的脑内肿瘤(n = 80)、多发性硬化病变(n = 10)、脓肿(n = 4)、神经狼疮(n = 15)和中风(n = 16)的增强T2*加权灌注成像中的价值。所有实施的操作都是安全的,未发生不良事件。除两名患者外,所有获取的灌注图像质量良好。我们的研究结果证实,像MultiHance这样的高弛豫率造影剂非常适合用于中枢神经系统的灌注MRI。